| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Pressure | 38 | 2021 | 496 | 3.570 |
Why?
|
| Postural Orthostatic Tachycardia Syndrome | 23 | 2021 | 34 | 3.470 |
Why?
|
| Hypotension, Orthostatic | 18 | 2019 | 26 | 2.380 |
Why?
|
| Autonomic Nervous System Diseases | 15 | 2020 | 19 | 2.000 |
Why?
|
| Baroreflex | 11 | 2019 | 19 | 1.750 |
Why?
|
| Posture | 12 | 2021 | 127 | 1.570 |
Why?
|
| Menstrual Cycle | 6 | 2021 | 81 | 1.510 |
Why?
|
| Heart Rate | 23 | 2021 | 307 | 1.480 |
Why?
|
| Multiple System Atrophy | 7 | 2017 | 13 | 1.210 |
Why?
|
| Anti-Mullerian Hormone | 4 | 2022 | 62 | 1.180 |
Why?
|
| Pure Autonomic Failure | 7 | 2018 | 8 | 1.170 |
Why?
|
| Sympathetic Nervous System | 12 | 2019 | 34 | 1.060 |
Why?
|
| Menopause | 4 | 2020 | 249 | 1.050 |
Why?
|
| Ovarian Follicle | 5 | 2022 | 39 | 1.020 |
Why?
|
| Tachycardia | 5 | 2012 | 28 | 0.970 |
Why?
|
| Blood Volume | 5 | 2014 | 42 | 0.940 |
Why?
|
| Hypertension | 12 | 2019 | 570 | 0.880 |
Why?
|
| Kidney | 4 | 2017 | 414 | 0.880 |
Why?
|
| Inhibins | 4 | 2020 | 50 | 0.870 |
Why?
|
| Follicle Stimulating Hormone | 4 | 2020 | 82 | 0.870 |
Why?
|
| Autonomic Nervous System | 12 | 2016 | 34 | 0.870 |
Why?
|
| Benzhydryl Compounds | 4 | 2014 | 48 | 0.820 |
Why?
|
| Betacoronavirus | 2 | 2025 | 166 | 0.810 |
Why?
|
| Cross-Over Studies | 19 | 2021 | 153 | 0.800 |
Why?
|
| Humans | 115 | 2025 | 59389 | 0.790 |
Why?
|
| Immunity, Herd | 1 | 2021 | 1 | 0.750 |
Why?
|
| Mass Vaccination | 1 | 2021 | 9 | 0.740 |
Why?
|
| Aging | 5 | 2020 | 710 | 0.730 |
Why?
|
| Growth Differentiation Factor 9 | 6 | 2022 | 9 | 0.730 |
Why?
|
| Spike Glycoprotein, Coronavirus | 4 | 2022 | 95 | 0.700 |
Why?
|
| Cell Count | 1 | 2020 | 127 | 0.690 |
Why?
|
| Infertility, Female | 2 | 2019 | 44 | 0.670 |
Why?
|
| Norepinephrine | 8 | 2021 | 98 | 0.660 |
Why?
|
| Fertilization in Vitro | 2 | 2019 | 83 | 0.660 |
Why?
|
| Pain | 3 | 2007 | 396 | 0.650 |
Why?
|
| Female | 71 | 2022 | 30726 | 0.650 |
Why?
|
| Adult | 48 | 2021 | 15681 | 0.620 |
Why?
|
| Bone Morphogenetic Protein 15 | 5 | 2022 | 8 | 0.610 |
Why?
|
| Phylogeny | 10 | 2025 | 337 | 0.590 |
Why?
|
| Angiotensin II | 3 | 2012 | 23 | 0.580 |
Why?
|
| Hemodynamics | 6 | 2016 | 230 | 0.560 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 192 | 0.560 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 205 | 0.550 |
Why?
|
| Vasoconstrictor Agents | 4 | 2019 | 64 | 0.550 |
Why?
|
| Drinking | 1 | 2017 | 13 | 0.550 |
Why?
|
| Male | 56 | 2021 | 27749 | 0.530 |
Why?
|
| Solitary Nucleus | 1 | 2015 | 6 | 0.500 |
Why?
|
| Central Nervous System Stimulants | 2 | 2007 | 63 | 0.490 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2015 | 40 | 0.490 |
Why?
|
| Natriuresis | 2 | 2013 | 7 | 0.490 |
Why?
|
| Wnt Proteins | 1 | 2015 | 91 | 0.480 |
Why?
|
| Evolution, Molecular | 4 | 2025 | 298 | 0.480 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2015 | 55 | 0.480 |
Why?
|
| Middle Aged | 37 | 2021 | 16314 | 0.470 |
Why?
|
| Young Adult | 16 | 2021 | 4272 | 0.470 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 446 | 0.470 |
Why?
|
| Adrenergic alpha-2 Receptor Antagonists | 3 | 2012 | 4 | 0.460 |
Why?
|
| Yohimbine | 3 | 2012 | 8 | 0.460 |
Why?
|
| Papillomavirus Vaccines | 3 | 2020 | 67 | 0.460 |
Why?
|
| Shc Signaling Adaptor Proteins | 1 | 2013 | 5 | 0.440 |
Why?
|
| Gene Dosage | 1 | 2013 | 60 | 0.430 |
Why?
|
| Primary Dysautonomias | 2 | 2019 | 7 | 0.430 |
Why?
|
| Vicia faba | 1 | 2013 | 3 | 0.420 |
Why?
|
| Chiroptera | 2 | 2025 | 10 | 0.420 |
Why?
|
| Insulin | 3 | 2015 | 673 | 0.420 |
Why?
|
| Supine Position | 7 | 2019 | 31 | 0.410 |
Why?
|
| Pyridostigmine Bromide | 2 | 2019 | 5 | 0.400 |
Why?
|
| Syncope | 2 | 2016 | 41 | 0.400 |
Why?
|
| Sodium Chloride, Dietary | 2 | 2017 | 10 | 0.400 |
Why?
|
| Liver | 1 | 2017 | 795 | 0.400 |
Why?
|
| Dopamine | 1 | 2013 | 102 | 0.400 |
Why?
|
| Space Flight | 2 | 2015 | 17 | 0.400 |
Why?
|
| Gene Deletion | 1 | 2013 | 293 | 0.400 |
Why?
|
| Propylamines | 4 | 2014 | 8 | 0.390 |
Why?
|
| Double-Blind Method | 9 | 2015 | 715 | 0.390 |
Why?
|
| Treatment Outcome | 17 | 2019 | 5283 | 0.380 |
Why?
|
| Catecholamines | 5 | 2019 | 29 | 0.370 |
Why?
|
| Polycystic Ovary Syndrome | 2 | 2022 | 22 | 0.370 |
Why?
|
| Viruses | 2 | 2022 | 78 | 0.370 |
Why?
|
| Perioperative Care | 1 | 2012 | 76 | 0.360 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 2 | 2007 | 20 | 0.360 |
Why?
|
| Pain Threshold | 2 | 2007 | 25 | 0.350 |
Why?
|
| Pressoreceptors | 2 | 2009 | 4 | 0.350 |
Why?
|
| Recombination, Genetic | 4 | 2020 | 238 | 0.340 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 4 | 2013 | 9 | 0.330 |
Why?
|
| Propranolol | 1 | 2009 | 21 | 0.330 |
Why?
|
| Fatigue Syndrome, Chronic | 4 | 2020 | 9 | 0.320 |
Why?
|
| Adrenergic Uptake Inhibitors | 4 | 2014 | 14 | 0.310 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2009 | 147 | 0.300 |
Why?
|
| Adolescent | 10 | 2020 | 5838 | 0.290 |
Why?
|
| Papillomavirus Infections | 2 | 2019 | 120 | 0.290 |
Why?
|
| HIV-1 | 5 | 2014 | 692 | 0.290 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2007 | 15 | 0.290 |
Why?
|
| Fatigue | 2 | 2011 | 103 | 0.290 |
Why?
|
| Pandemics | 3 | 2021 | 617 | 0.290 |
Why?
|
| Plasma Volume | 1 | 2007 | 4 | 0.280 |
Why?
|
| Genome, Viral | 4 | 2025 | 120 | 0.280 |
Why?
|
| Administration, Oral | 6 | 2015 | 355 | 0.270 |
Why?
|
| Oocytes | 4 | 2022 | 193 | 0.270 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2015 | 805 | 0.270 |
Why?
|
| Immune Evasion | 3 | 2021 | 55 | 0.260 |
Why?
|
| Aged | 25 | 2018 | 13408 | 0.260 |
Why?
|
| Sodium Chloride | 1 | 2006 | 60 | 0.260 |
Why?
|
| Atomoxetine Hydrochloride | 5 | 2019 | 6 | 0.260 |
Why?
|
| Hemoglobins | 2 | 2011 | 133 | 0.260 |
Why?
|
| Affect | 1 | 2007 | 123 | 0.250 |
Why?
|
| Midodrine | 2 | 2016 | 3 | 0.250 |
Why?
|
| Mice, Knockout | 2 | 2017 | 1994 | 0.250 |
Why?
|
| Adrenal Medulla | 1 | 2005 | 5 | 0.240 |
Why?
|
| Metanephrine | 1 | 2004 | 1 | 0.240 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2005 | 45 | 0.240 |
Why?
|
| Biomarkers | 8 | 2022 | 1307 | 0.240 |
Why?
|
| Animals | 13 | 2025 | 19650 | 0.230 |
Why?
|
| Vagus Nerve | 2 | 2019 | 20 | 0.230 |
Why?
|
| Anemia | 1 | 2006 | 119 | 0.230 |
Why?
|
| Water | 2 | 2006 | 300 | 0.230 |
Why?
|
| Mutation | 6 | 2022 | 2456 | 0.220 |
Why?
|
| Muscle, Skeletal | 4 | 2019 | 674 | 0.210 |
Why?
|
| Tilt-Table Test | 4 | 2015 | 11 | 0.210 |
Why?
|
| Parkinson Disease | 2 | 2017 | 125 | 0.210 |
Why?
|
| Neuropeptides | 1 | 2004 | 83 | 0.210 |
Why?
|
| Renin | 2 | 2013 | 10 | 0.210 |
Why?
|
| Membrane Transport Proteins | 1 | 2004 | 123 | 0.210 |
Why?
|
| Follow-Up Studies | 8 | 2019 | 2338 | 0.210 |
Why?
|
| Nitric Oxide | 2 | 2014 | 146 | 0.210 |
Why?
|
| Sleep Wake Disorders | 2 | 2016 | 65 | 0.200 |
Why?
|
| Endometriosis | 1 | 2022 | 24 | 0.200 |
Why?
|
| Vasopressins | 1 | 2002 | 15 | 0.190 |
Why?
|
| Viruses, Unclassified | 1 | 2021 | 1 | 0.190 |
Why?
|
| Classification | 1 | 2021 | 11 | 0.190 |
Why?
|
| Antihypertensive Agents | 3 | 2015 | 163 | 0.190 |
Why?
|
| Consensus | 2 | 2020 | 193 | 0.190 |
Why?
|
| Sodium, Dietary | 1 | 2021 | 9 | 0.190 |
Why?
|
| Public Opinion | 1 | 2021 | 22 | 0.180 |
Why?
|
| Syncope, Vasovagal | 2 | 2011 | 8 | 0.180 |
Why?
|
| Independent Living | 1 | 2021 | 44 | 0.180 |
Why?
|
| Exercise Tolerance | 2 | 2014 | 75 | 0.180 |
Why?
|
| Case-Control Studies | 7 | 2022 | 1051 | 0.180 |
Why?
|
| Genetic Fitness | 1 | 2021 | 30 | 0.180 |
Why?
|
| Home Care Services | 1 | 2021 | 97 | 0.170 |
Why?
|
| Societies, Medical | 2 | 2019 | 337 | 0.170 |
Why?
|
| Autoimmune Diseases of the Nervous System | 2 | 2010 | 10 | 0.170 |
Why?
|
| Healthy Volunteers | 1 | 2020 | 66 | 0.170 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2020 | 42 | 0.170 |
Why?
|
| Bayes Theorem | 1 | 2020 | 110 | 0.170 |
Why?
|
| Hormones | 2 | 2015 | 60 | 0.170 |
Why?
|
| Complex Regional Pain Syndromes | 1 | 2019 | 1 | 0.170 |
Why?
|
| China | 1 | 2020 | 134 | 0.170 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 297 | 0.170 |
Why?
|
| Phenotype | 1 | 2004 | 1137 | 0.170 |
Why?
|
| Amino Acid Substitution | 1 | 2020 | 234 | 0.170 |
Why?
|
| Societies, Scientific | 1 | 2020 | 32 | 0.170 |
Why?
|
| Gonadotropins | 1 | 2019 | 14 | 0.170 |
Why?
|
| Ovary | 3 | 2019 | 98 | 0.160 |
Why?
|
| Papillomaviridae | 1 | 2019 | 58 | 0.160 |
Why?
|
| Prospective Studies | 8 | 2018 | 3067 | 0.160 |
Why?
|
| Luteal Cells | 1 | 2019 | 2 | 0.160 |
Why?
|
| Genetic Variation | 2 | 2020 | 357 | 0.160 |
Why?
|
| Valsalva Maneuver | 2 | 2016 | 11 | 0.160 |
Why?
|
| Genetic Loci | 1 | 2019 | 107 | 0.160 |
Why?
|
| Pressure | 3 | 2015 | 76 | 0.160 |
Why?
|
| Activins | 1 | 2019 | 54 | 0.160 |
Why?
|
| Circadian Rhythm | 3 | 2014 | 373 | 0.160 |
Why?
|
| Heart Defects, Congenital | 1 | 2019 | 94 | 0.150 |
Why?
|
| Polysomnography | 2 | 2016 | 55 | 0.150 |
Why?
|
| Sodium | 3 | 2013 | 60 | 0.150 |
Why?
|
| Single-Blind Method | 5 | 2019 | 136 | 0.140 |
Why?
|
| Hypovolemia | 2 | 2007 | 16 | 0.140 |
Why?
|
| History, 21st Century | 1 | 2018 | 162 | 0.140 |
Why?
|
| Autonomic Denervation | 1 | 2017 | 1 | 0.140 |
Why?
|
| Splanchnic Nerves | 1 | 2017 | 3 | 0.140 |
Why?
|
| Hypotonic Solutions | 1 | 2017 | 8 | 0.140 |
Why?
|
| History, 20th Century | 1 | 2018 | 224 | 0.140 |
Why?
|
| Blood Pressure Determination | 4 | 2019 | 37 | 0.140 |
Why?
|
| Reference Values | 3 | 2007 | 326 | 0.140 |
Why?
|
| Hematocrit | 2 | 2008 | 32 | 0.140 |
Why?
|
| Lewy Body Disease | 1 | 2017 | 14 | 0.140 |
Why?
|
| Jugular Veins | 1 | 2017 | 29 | 0.140 |
Why?
|
| TRPV Cation Channels | 1 | 2017 | 18 | 0.140 |
Why?
|
| Duodenum | 1 | 2017 | 42 | 0.140 |
Why?
|
| Portal Vein | 1 | 2017 | 38 | 0.140 |
Why?
|
| Osmolar Concentration | 1 | 2017 | 88 | 0.140 |
Why?
|
| Time Factors | 8 | 2019 | 3617 | 0.130 |
Why?
|
| Drinking Water | 1 | 2017 | 18 | 0.130 |
Why?
|
| Intermittent Pneumatic Compression Devices | 1 | 2016 | 1 | 0.130 |
Why?
|
| Cardiovascular Diseases | 2 | 2018 | 789 | 0.130 |
Why?
|
| Systole | 4 | 2017 | 109 | 0.130 |
Why?
|
| Splanchnic Circulation | 1 | 2016 | 16 | 0.130 |
Why?
|
| Interleukin-1beta | 1 | 2018 | 258 | 0.130 |
Why?
|
| Action Potentials | 2 | 2007 | 101 | 0.130 |
Why?
|
| Cryopreservation | 1 | 2016 | 27 | 0.130 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2016 | 31 | 0.130 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2016 | 5 | 0.130 |
Why?
|
| Epithelium | 1 | 2016 | 96 | 0.130 |
Why?
|
| Models, Animal | 1 | 2017 | 221 | 0.130 |
Why?
|
| Stroke Volume | 2 | 2015 | 314 | 0.130 |
Why?
|
| Neurodegenerative Diseases | 1 | 2018 | 134 | 0.130 |
Why?
|
| Spironolactone | 1 | 2015 | 9 | 0.130 |
Why?
|
| RNA, Viral | 5 | 2014 | 259 | 0.120 |
Why?
|
| Patient Isolation | 1 | 2015 | 7 | 0.120 |
Why?
|
| Carotid Body Tumor | 1 | 2015 | 2 | 0.120 |
Why?
|
| HIV Envelope Protein gp120 | 2 | 2014 | 130 | 0.120 |
Why?
|
| Airway Resistance | 1 | 2015 | 11 | 0.120 |
Why?
|
| Infusions, Intravenous | 2 | 2014 | 163 | 0.120 |
Why?
|
| Inhalation | 1 | 2015 | 10 | 0.120 |
Why?
|
| Government Programs | 1 | 2015 | 20 | 0.120 |
Why?
|
| Restraint, Physical | 1 | 2015 | 33 | 0.120 |
Why?
|
| HIV Infections | 4 | 2009 | 913 | 0.120 |
Why?
|
| Benzopyrans | 1 | 2014 | 7 | 0.120 |
Why?
|
| Metoprolol | 1 | 2014 | 11 | 0.120 |
Why?
|
| Ethanolamines | 1 | 2014 | 17 | 0.120 |
Why?
|
| Insulin Resistance | 2 | 2015 | 392 | 0.120 |
Why?
|
| Chronic Disease | 2 | 2007 | 717 | 0.110 |
Why?
|
| Placebo Effect | 1 | 2014 | 10 | 0.110 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2014 | 35 | 0.110 |
Why?
|
| Sinoatrial Node | 1 | 2014 | 3 | 0.110 |
Why?
|
| Tachycardia, Sinus | 1 | 2014 | 3 | 0.110 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2014 | 10 | 0.110 |
Why?
|
| Parasympathetic Nervous System | 1 | 2014 | 6 | 0.110 |
Why?
|
| Algorithms | 3 | 2014 | 974 | 0.110 |
Why?
|
| Melatonin | 1 | 2014 | 66 | 0.110 |
Why?
|
| Rifampin | 1 | 2014 | 23 | 0.110 |
Why?
|
| Ganglia, Autonomic | 2 | 2010 | 2 | 0.110 |
Why?
|
| Src Homology 2 Domain-Containing, Transforming Protein 2 | 1 | 2013 | 1 | 0.110 |
Why?
|
| Ovarian Diseases | 1 | 2014 | 19 | 0.110 |
Why?
|
| Viral Tropism | 1 | 2014 | 50 | 0.110 |
Why?
|
| Placebos | 2 | 2014 | 68 | 0.110 |
Why?
|
| Age Factors | 2 | 2015 | 1504 | 0.110 |
Why?
|
| Integrases | 1 | 2014 | 36 | 0.110 |
Why?
|
| Epithelial Cells | 1 | 2016 | 391 | 0.110 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2014 | 96 | 0.110 |
Why?
|
| Dihydroxyphenylalanine | 1 | 2013 | 1 | 0.110 |
Why?
|
| Catechols | 1 | 2013 | 6 | 0.110 |
Why?
|
| Levodopa | 1 | 2013 | 8 | 0.110 |
Why?
|
| United States | 5 | 2019 | 7426 | 0.110 |
Why?
|
| Cognition Disorders | 1 | 2015 | 215 | 0.100 |
Why?
|
| Weightlessness Countermeasures | 2 | 2015 | 2 | 0.100 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2012 | 12 | 0.100 |
Why?
|
| Ventricular Function, Left | 1 | 2014 | 257 | 0.100 |
Why?
|
| Cohort Studies | 5 | 2018 | 2375 | 0.100 |
Why?
|
| Decision Support Techniques | 1 | 2014 | 180 | 0.100 |
Why?
|
| Weightlessness | 2 | 2015 | 11 | 0.100 |
Why?
|
| Antidiuretic Agents | 1 | 2012 | 2 | 0.100 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2012 | 3 | 0.100 |
Why?
|
| Disease Progression | 1 | 2017 | 1119 | 0.100 |
Why?
|
| Shy-Drager Syndrome | 1 | 2012 | 2 | 0.100 |
Why?
|
| Computational Biology | 1 | 2014 | 333 | 0.100 |
Why?
|
| Hyperventilation | 1 | 2012 | 4 | 0.100 |
Why?
|
| Hemostatics | 1 | 2012 | 26 | 0.100 |
Why?
|
| Cross-Sectional Studies | 4 | 2022 | 2382 | 0.100 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 1091 | 0.090 |
Why?
|
| Mental Health Services | 1 | 2015 | 269 | 0.090 |
Why?
|
| Drug Interactions | 1 | 2012 | 115 | 0.090 |
Why?
|
| Anesthesia | 1 | 2012 | 48 | 0.090 |
Why?
|
| Blood Vessels | 2 | 2009 | 62 | 0.090 |
Why?
|
| Sympatholytics | 2 | 2014 | 5 | 0.090 |
Why?
|
| Postoperative Care | 1 | 2012 | 115 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 2 | 2017 | 3231 | 0.090 |
Why?
|
| Airway Management | 1 | 2012 | 55 | 0.090 |
Why?
|
| Nervous System Diseases | 1 | 2012 | 104 | 0.090 |
Why?
|
| Renin-Angiotensin System | 1 | 2011 | 21 | 0.090 |
Why?
|
| Tennessee | 3 | 2015 | 16 | 0.090 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2011 | 26 | 0.090 |
Why?
|
| DNA, Viral | 2 | 2014 | 223 | 0.090 |
Why?
|
| Sympathetic Fibers, Postganglionic | 2 | 2009 | 2 | 0.090 |
Why?
|
| Hyperglycemia | 1 | 2011 | 98 | 0.090 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2014 | 349 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2010 | 57 | 0.090 |
Why?
|
| Lymphoma, B-Cell | 1 | 2010 | 59 | 0.090 |
Why?
|
| Cardiovascular System | 3 | 2007 | 38 | 0.090 |
Why?
|
| Virulence | 2 | 2021 | 188 | 0.090 |
Why?
|
| Syndrome | 2 | 2007 | 170 | 0.090 |
Why?
|
| Myasthenia Gravis | 1 | 2010 | 7 | 0.080 |
Why?
|
| Respiratory Mechanics | 2 | 2009 | 57 | 0.080 |
Why?
|
| Drug Administration Schedule | 2 | 2014 | 284 | 0.080 |
Why?
|
| Gorilla gorilla | 1 | 2009 | 3 | 0.080 |
Why?
|
| Antibodies, Neutralizing | 2 | 2021 | 178 | 0.080 |
Why?
|
| Molecular Sequence Data | 6 | 2014 | 1951 | 0.080 |
Why?
|
| Carotid Body | 1 | 2009 | 1 | 0.080 |
Why?
|
| Diet | 1 | 2013 | 497 | 0.080 |
Why?
|
| Quality of Life | 2 | 2019 | 1137 | 0.080 |
Why?
|
| Health Care Surveys | 1 | 2010 | 278 | 0.080 |
Why?
|
| HIV | 1 | 2009 | 68 | 0.080 |
Why?
|
| Antibodies, Viral | 2 | 2021 | 292 | 0.080 |
Why?
|
| Hospitalization | 2 | 2007 | 1292 | 0.080 |
Why?
|
| Pharmaceutical Preparations | 1 | 2010 | 117 | 0.080 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 2009 | 53 | 0.080 |
Why?
|
| Functional Laterality | 1 | 2009 | 133 | 0.080 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2010 | 147 | 0.070 |
Why?
|
| Hyperalgesia | 1 | 2007 | 12 | 0.070 |
Why?
|
| Fluid Shifts | 1 | 2007 | 1 | 0.070 |
Why?
|
| Gravitation | 1 | 2007 | 10 | 0.070 |
Why?
|
| Endocrine Glands | 1 | 2007 | 6 | 0.070 |
Why?
|
| Fingers | 1 | 2007 | 43 | 0.070 |
Why?
|
| Sleep Apnea, Central | 1 | 2007 | 7 | 0.070 |
Why?
|
| Exercise | 1 | 2014 | 883 | 0.070 |
Why?
|
| Amino Acid Sequence | 3 | 2021 | 1553 | 0.070 |
Why?
|
| Aspergillosis | 1 | 2007 | 40 | 0.070 |
Why?
|
| Retrospective Studies | 3 | 2015 | 6071 | 0.070 |
Why?
|
| Hot Temperature | 1 | 2007 | 126 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 3 | 2014 | 495 | 0.070 |
Why?
|
| Electrodiagnosis | 1 | 2007 | 14 | 0.070 |
Why?
|
| Reproduction | 1 | 2007 | 89 | 0.070 |
Why?
|
| Pattern Recognition, Automated | 1 | 2007 | 51 | 0.070 |
Why?
|
| Dizziness | 1 | 2006 | 16 | 0.070 |
Why?
|
| Electrophysiology | 1 | 2006 | 87 | 0.070 |
Why?
|
| Internet | 1 | 2010 | 448 | 0.070 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2007 | 42 | 0.070 |
Why?
|
| Food, Formulated | 1 | 2006 | 10 | 0.070 |
Why?
|
| Cell Line | 4 | 2021 | 1983 | 0.060 |
Why?
|
| Predictive Value of Tests | 3 | 2017 | 1027 | 0.060 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2006 | 96 | 0.060 |
Why?
|
| Evans Blue | 1 | 2006 | 1 | 0.060 |
Why?
|
| Serum Albumin, Radio-Iodinated | 1 | 2006 | 1 | 0.060 |
Why?
|
| Neoplasms | 1 | 2016 | 1231 | 0.060 |
Why?
|
| Clonidine | 1 | 2006 | 24 | 0.060 |
Why?
|
| Models, Cardiovascular | 1 | 2006 | 76 | 0.060 |
Why?
|
| HEK293 Cells | 2 | 2021 | 587 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2011 | 2516 | 0.060 |
Why?
|
| Injections, Intravenous | 1 | 2006 | 155 | 0.060 |
Why?
|
| Drug Synergism | 2 | 2019 | 132 | 0.060 |
Why?
|
| Coloring Agents | 1 | 2006 | 53 | 0.060 |
Why?
|
| Homeodomain Proteins | 1 | 2007 | 254 | 0.060 |
Why?
|
| Phylogeography | 1 | 2025 | 4 | 0.060 |
Why?
|
| Disease Reservoirs | 1 | 2025 | 9 | 0.060 |
Why?
|
| Diuresis | 1 | 2005 | 5 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 628 | 0.060 |
Why?
|
| Viral Load | 2 | 2003 | 220 | 0.060 |
Why?
|
| Electrolytes | 1 | 2005 | 25 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 725 | 0.060 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2004 | 7 | 0.060 |
Why?
|
| Radiopharmaceuticals | 1 | 2006 | 181 | 0.060 |
Why?
|
| Half-Life | 1 | 2004 | 75 | 0.060 |
Why?
|
| Electrocardiography | 3 | 2014 | 523 | 0.060 |
Why?
|
| Risk Factors | 3 | 2014 | 4986 | 0.060 |
Why?
|
| United Kingdom | 2 | 2020 | 66 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 451 | 0.060 |
Why?
|
| Progesterone | 3 | 2015 | 158 | 0.060 |
Why?
|
| Models, Neurological | 1 | 2004 | 79 | 0.060 |
Why?
|
| Vesicular Biogenic Amine Transport Proteins | 1 | 2004 | 1 | 0.060 |
Why?
|
| Models, Chemical | 1 | 2004 | 137 | 0.060 |
Why?
|
| Vesicular Monoamine Transport Proteins | 1 | 2004 | 2 | 0.060 |
Why?
|
| Dopamine beta-Hydroxylase | 1 | 2004 | 12 | 0.060 |
Why?
|
| Lung Neoplasms | 1 | 2010 | 584 | 0.060 |
Why?
|
| Estradiol | 3 | 2015 | 247 | 0.060 |
Why?
|
| Symporters | 1 | 2004 | 13 | 0.060 |
Why?
|
| Gene Products, pol | 1 | 2003 | 8 | 0.060 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2003 | 33 | 0.050 |
Why?
|
| Papio | 1 | 2003 | 12 | 0.050 |
Why?
|
| Pain Measurement | 1 | 2004 | 327 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 3 | 2014 | 394 | 0.050 |
Why?
|
| Stress Disorders, Traumatic | 1 | 2003 | 8 | 0.050 |
Why?
|
| Committee Membership | 1 | 2022 | 5 | 0.050 |
Why?
|
| Acute Disease | 1 | 2004 | 658 | 0.050 |
Why?
|
| Emigration and Immigration | 1 | 2003 | 25 | 0.050 |
Why?
|
| Adrenergic Fibers | 1 | 2002 | 1 | 0.050 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2003 | 51 | 0.050 |
Why?
|
| Neuroglia | 1 | 2003 | 79 | 0.050 |
Why?
|
| HIV-2 | 1 | 2002 | 23 | 0.050 |
Why?
|
| Simian Immunodeficiency Virus | 1 | 2003 | 68 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 5119 | 0.050 |
Why?
|
| Life Change Events | 1 | 2003 | 65 | 0.050 |
Why?
|
| Follicular Phase | 2 | 2015 | 15 | 0.050 |
Why?
|
| Luteal Phase | 2 | 2015 | 28 | 0.050 |
Why?
|
| Drug Resistance, Viral | 1 | 2003 | 156 | 0.050 |
Why?
|
| tau Proteins | 1 | 2003 | 191 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2014 | 589 | 0.050 |
Why?
|
| Economics, Nursing | 1 | 2021 | 1 | 0.050 |
Why?
|
| Viroids | 1 | 2021 | 1 | 0.050 |
Why?
|
| Refugees | 1 | 2003 | 66 | 0.050 |
Why?
|
| Genetic Drift | 1 | 2021 | 16 | 0.050 |
Why?
|
| Zoonoses | 1 | 2021 | 7 | 0.050 |
Why?
|
| Genes, Viral | 1 | 2021 | 55 | 0.050 |
Why?
|
| Laboratories | 1 | 2021 | 27 | 0.050 |
Why?
|
| Sweating | 2 | 2012 | 26 | 0.050 |
Why?
|
| Codon | 1 | 2021 | 48 | 0.050 |
Why?
|
| Vero Cells | 1 | 2021 | 76 | 0.050 |
Why?
|
| International Cooperation | 1 | 2021 | 84 | 0.050 |
Why?
|
| Neuropsychological Tests | 2 | 2015 | 371 | 0.050 |
Why?
|
| Malnutrition | 1 | 2021 | 40 | 0.050 |
Why?
|
| Blood Glucose | 2 | 2015 | 461 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2017 | 1793 | 0.040 |
Why?
|
| Sleep | 2 | 2016 | 215 | 0.040 |
Why?
|
| Aspartic Acid | 1 | 2020 | 28 | 0.040 |
Why?
|
| Glycine | 1 | 2020 | 46 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 661 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2020 | 63 | 0.040 |
Why?
|
| Biological Evolution | 1 | 2021 | 114 | 0.040 |
Why?
|
| Plasma Exchange | 2 | 2010 | 21 | 0.040 |
Why?
|
| Accidental Falls | 1 | 2021 | 124 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2019 | 1552 | 0.040 |
Why?
|
| Superovulation | 1 | 2019 | 3 | 0.040 |
Why?
|
| Gene Duplication | 1 | 2019 | 31 | 0.040 |
Why?
|
| Follicular Fluid | 1 | 2019 | 14 | 0.040 |
Why?
|
| Public Health | 1 | 2021 | 176 | 0.040 |
Why?
|
| Base Sequence | 3 | 2009 | 1302 | 0.040 |
Why?
|
| Recurrence | 1 | 2021 | 602 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 65 | 0.040 |
Why?
|
| Chorionic Gonadotropin | 1 | 2019 | 14 | 0.040 |
Why?
|
| Information Storage and Retrieval | 1 | 2019 | 60 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2007 | 1471 | 0.040 |
Why?
|
| Homeostasis | 1 | 2002 | 346 | 0.040 |
Why?
|
| Oocyte Retrieval | 1 | 2019 | 12 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2019 | 83 | 0.040 |
Why?
|
| Genotype | 2 | 2014 | 617 | 0.040 |
Why?
|
| Mice | 3 | 2014 | 10291 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2014 | 238 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2021 | 327 | 0.040 |
Why?
|
| Receptors, Interleukin-1 Type I | 1 | 2018 | 9 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2019 | 115 | 0.040 |
Why?
|
| Interleukin-33 | 1 | 2018 | 18 | 0.040 |
Why?
|
| Linear Models | 2 | 2011 | 403 | 0.040 |
Why?
|
| Nevada | 1 | 2017 | 2 | 0.040 |
Why?
|
| Multigene Family | 1 | 2018 | 92 | 0.040 |
Why?
|
| Europe | 1 | 2018 | 182 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2015 | 1925 | 0.040 |
Why?
|
| Interleukin-18 | 1 | 2018 | 71 | 0.040 |
Why?
|
| Muscle Contraction | 1 | 2019 | 197 | 0.040 |
Why?
|
| Vertebrates | 1 | 2018 | 41 | 0.040 |
Why?
|
| Patient Advocacy | 1 | 2017 | 38 | 0.040 |
Why?
|
| Nitroglycerin | 2 | 2008 | 11 | 0.040 |
Why?
|
| Vasodilator Agents | 2 | 2008 | 63 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2017 | 141 | 0.030 |
Why?
|
| Diastole | 1 | 2017 | 89 | 0.030 |
Why?
|
| Protein Binding | 1 | 2021 | 1555 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2004 | 2050 | 0.030 |
Why?
|
| Child | 2 | 2017 | 4189 | 0.030 |
Why?
|
| Age of Onset | 1 | 2017 | 170 | 0.030 |
Why?
|
| Demography | 2 | 2010 | 169 | 0.030 |
Why?
|
| Peritoneal Cavity | 1 | 2016 | 31 | 0.030 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2016 | 20 | 0.030 |
Why?
|
| ROC Curve | 1 | 2017 | 267 | 0.030 |
Why?
|
| Telemedicine | 1 | 2021 | 308 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 2009 | 111 | 0.030 |
Why?
|
| Dextrans | 1 | 2016 | 45 | 0.030 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2015 | 12 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2003 | 720 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 2016 | 177 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2007 | 93 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2016 | 149 | 0.030 |
Why?
|
| Suction | 1 | 2015 | 33 | 0.030 |
Why?
|
| Stroop Test | 1 | 2015 | 7 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 1559 | 0.030 |
Why?
|
| New York | 1 | 2015 | 134 | 0.030 |
Why?
|
| Nebivolol | 1 | 2014 | 1 | 0.030 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 1 | 2014 | 4 | 0.030 |
Why?
|
| Adrenergic alpha-1 Receptor Agonists | 1 | 2014 | 3 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2016 | 260 | 0.030 |
Why?
|
| Hypertension, Pulmonary | 1 | 2016 | 92 | 0.030 |
Why?
|
| Patient Positioning | 1 | 2015 | 44 | 0.030 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2015 | 36 | 0.030 |
Why?
|
| Anaerobic Threshold | 1 | 2014 | 12 | 0.030 |
Why?
|
| Blood | 1 | 2014 | 29 | 0.030 |
Why?
|
| Isotonic Solutions | 1 | 2014 | 14 | 0.030 |
Why?
|
| Vasodilation | 1 | 2014 | 35 | 0.030 |
Why?
|
| Research Design | 1 | 2017 | 555 | 0.030 |
Why?
|
| Parasympatholytics | 1 | 2014 | 6 | 0.030 |
Why?
|
| Executive Function | 1 | 2015 | 61 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2016 | 226 | 0.030 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2014 | 12 | 0.030 |
Why?
|
| Receptors, HIV | 1 | 2014 | 15 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2015 | 365 | 0.030 |
Why?
|
| Periodicity | 1 | 2014 | 49 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2014 | 61 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 2015 | 133 | 0.030 |
Why?
|
| Equipment Design | 1 | 2015 | 329 | 0.030 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 2014 | 34 | 0.030 |
Why?
|
| Electric Countershock | 1 | 2014 | 99 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2014 | 206 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 743 | 0.030 |
Why?
|
| Mutant Proteins | 1 | 2014 | 103 | 0.030 |
Why?
|
| Attention | 1 | 2015 | 146 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2014 | 134 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2015 | 458 | 0.030 |
Why?
|
| Orthostatic Intolerance | 1 | 2012 | 2 | 0.030 |
Why?
|
| omega-N-Methylarginine | 1 | 2013 | 8 | 0.030 |
Why?
|
| Phenylephrine | 1 | 2013 | 14 | 0.030 |
Why?
|
| Captopril | 1 | 2012 | 9 | 0.030 |
Why?
|
| Aldosterone | 1 | 2012 | 17 | 0.030 |
Why?
|
| Losartan | 1 | 2012 | 18 | 0.030 |
Why?
|
| Nitric Oxide Synthase | 1 | 2013 | 45 | 0.030 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2012 | 25 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2017 | 1284 | 0.030 |
Why?
|
| Exercise Test | 1 | 2014 | 242 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 527 | 0.030 |
Why?
|
| Infant | 1 | 2017 | 1492 | 0.020 |
Why?
|
| Prognosis | 1 | 2017 | 1597 | 0.020 |
Why?
|
| Anti-HIV Agents | 1 | 2014 | 153 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 263 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 656 | 0.020 |
Why?
|
| Sex Factors | 1 | 2015 | 935 | 0.020 |
Why?
|
| Patient Selection | 1 | 2014 | 465 | 0.020 |
Why?
|
| Epinephrine | 1 | 2012 | 41 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2012 | 93 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1238 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2016 | 695 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2016 | 986 | 0.020 |
Why?
|
| Postural Balance | 1 | 2012 | 60 | 0.020 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2011 | 30 | 0.020 |
Why?
|
| Defibrillators, Implantable | 1 | 2014 | 257 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2011 | 45 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2013 | 347 | 0.020 |
Why?
|
| Rituximab | 1 | 2010 | 80 | 0.020 |
Why?
|
| Medication Systems | 1 | 2010 | 17 | 0.020 |
Why?
|
| Receptors, Nicotinic | 1 | 2010 | 66 | 0.020 |
Why?
|
| Muscle Weakness | 1 | 2010 | 29 | 0.020 |
Why?
|
| Autoantibodies | 1 | 2010 | 172 | 0.020 |
Why?
|
| Electromyography | 1 | 2010 | 88 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2014 | 1128 | 0.020 |
Why?
|
| Oxygen | 1 | 2011 | 313 | 0.020 |
Why?
|
| Peroneal Nerve | 1 | 2009 | 4 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2014 | 2092 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2019 | 2900 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 914 | 0.020 |
Why?
|
| Creatinine | 1 | 2008 | 128 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1479 | 0.020 |
Why?
|
| Voriconazole | 1 | 2007 | 6 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2011 | 831 | 0.020 |
Why?
|
| Testicular Hormones | 1 | 2007 | 10 | 0.020 |
Why?
|
| Heart Function Tests | 1 | 2007 | 14 | 0.020 |
Why?
|
| Neurotransmitter Agents | 1 | 2007 | 41 | 0.020 |
Why?
|
| Triazoles | 1 | 2007 | 51 | 0.020 |
Why?
|
| Neck | 1 | 2007 | 46 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2007 | 116 | 0.020 |
Why?
|
| Luteinizing Hormone | 1 | 2007 | 98 | 0.020 |
Why?
|
| DNA Breaks | 1 | 2006 | 7 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2007 | 189 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 705 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 2007 | 120 | 0.020 |
Why?
|
| DNA, Recombinant | 1 | 2006 | 44 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2007 | 131 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2007 | 133 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2007 | 186 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2006 | 288 | 0.020 |
Why?
|
| Artifacts | 1 | 2006 | 125 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 191 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2006 | 284 | 0.020 |
Why?
|
| Virus Replication | 1 | 2006 | 305 | 0.010 |
Why?
|
| Romania | 1 | 2003 | 2 | 0.010 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2003 | 4 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2006 | 459 | 0.010 |
Why?
|
| Synucleins | 1 | 2003 | 2 | 0.010 |
Why?
|
| 14-3-3 Proteins | 1 | 2003 | 19 | 0.010 |
Why?
|
| Obesity | 1 | 2011 | 1166 | 0.010 |
Why?
|
| Pons | 1 | 2003 | 15 | 0.010 |
Why?
|
| Monkey Diseases | 1 | 2003 | 7 | 0.010 |
Why?
|
| alpha-Synuclein | 1 | 2003 | 29 | 0.010 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 2003 | 20 | 0.010 |
Why?
|
| Somalia | 1 | 2003 | 10 | 0.010 |
Why?
|
| Panic Disorder | 1 | 2002 | 31 | 0.010 |
Why?
|
| Cerebellum | 1 | 2003 | 91 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2002 | 90 | 0.010 |
Why?
|
| Proviruses | 1 | 2002 | 26 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 2003 | 156 | 0.010 |
Why?
|
| Species Specificity | 1 | 2003 | 329 | 0.010 |
Why?
|
| DNA Primers | 1 | 2002 | 289 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2002 | 146 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2003 | 270 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 583 | 0.010 |
Why?
|
| World Health Organization | 1 | 2002 | 30 | 0.010 |
Why?
|
| Pituitary Gland | 1 | 2002 | 51 | 0.010 |
Why?
|
| Androgens | 1 | 2002 | 47 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 847 | 0.010 |
Why?
|
| Neurons | 1 | 2006 | 863 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2003 | 418 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2007 | 1507 | 0.010 |
Why?
|
| Prevalence | 1 | 2003 | 1253 | 0.010 |
Why?
|
| Heart Failure | 1 | 2002 | 853 | 0.010 |
Why?
|